Hindustan Laboratories Ltd. IPO Details
Hindustan Laboratories was incorporated on June 14, 2017. The company is an Indian pharmaceutical manufacturer focused on large-scale production and supply of generic medicines to government institutions under a B2G model. It supplies patented-expired formulations to central and state government agencies under procurement contracts, ensuring consistent quality and brand identity across products
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 14.1 M | - | - | ₹0 | DRHP DOC |
Hindustan Laboratories issue details
Hindustan Laboratories has 14.1 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Hindustan Laboratories IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Hindustan Laboratories NUMBER OF SHARES ON OFFER
Hindustan Laboratories FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| H1FY26 | 112.6 | 18.2 | 6.8 | 5.3 | 22.6% |
| FY25 | 219.7 | 41.3 | 10.8 | 5.7 | 24.5% |
| FY24 | 186.4 | 34.1 | 19.9 | 15.7 | 23.7% |
| FY23 | 172.3 | 22.3 | 33.3 | 30.1 | 17.8% |
Hindustan Laboratories INFORMATION ON IPO ISSUE
About Hindustan Laboratories
Hindustan Laboratories was incorporated on June 14, 2017. The company is an Indian pharmaceutical manufacturer focused on large-scale production and supply of generic medicines to government institutions under a B2G model. It supplies patented-expired formulations to central and state government agencies under procurement contracts, ensuring consistent quality and brand identity across products
Object of the Issue
- Funding the working capital requirements
- General corporate purposes
Hindustan Laboratories - PROMOTERS
| Name |
|---|
| Rajesh Vasantray Doshi |
| Kunjal C Dedhia |
| Krishiv Rajesh Doshi |
Hindustan Laboratories - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Rajesh Vasantray Doshi | Chairman & Managing Director |
| Kunjal C Dedhia | Executive Director |
| Krishiv Rajesh Doshi | Executive Director |
| Dambarudhar Sahu | Independent Director |
| Bhavik J Sanghavi | Independent Director |
| Ishika Bansal | Independent Director |
Hindustan Laboratories Book Running Lead Manager
Choice Capital Advisors Private Limited
hll.ipo@choiceindia.com
Hindustan Laboratories Registrar to the Offer
MUFG Intime India Private Limited
hindustanlaboratories.ipo@in.mpms.mufg.com
Hindustan Laboratories Strengths
Diversified product portfolio
The company primarily manufactures generic medicines with expired patents that serve as affordable alternatives to branded drugs. Its diversified portfolio covers multiple therapeutic areas, addressing both acute and chronic healthcare needs
Manufacturing capabilities
The company operates a well-connected manufacturing facility at Palghar, Maharashtra, producing multiple dosage forms with approvals for over 900 formulations. Its versatile and flexible infrastructure allows quick changes in product mix to meet evolving market demand
Government tenders
The company develops, manufactures, and supplies generic medicines primarily to government customers under tender-based procurement contracts. Revenue depends on successful bids, and its strong tender track record and compliance capabilities provide an advantage over new entrants
Hindustan Laboratories Risks
Competition
The company operates in a highly competitive generic pharmaceuticals market, competing on product range, quality, delivery, flexibility, and cost efficiency. Stronger competitors and pricing pressure or changing customer requirements could reduce market share and adversely affect financial performance
Expansion risks
The company plans to expand its generic formulations business internationally through government tenders in semi-regulated and unregulated markets. Failure to manage export-related risks, approvals, or licensing requirements could adversely impact its business and financial performance
New product acceptance risks
The company plans to enter cosmetic manufacturing and supply as a new business segment, including products such as skincare and personal care items, produced at its Palghar facility. If these products fail to gain market acceptance, win government tenders, or achieve scale efficiently, the expansion could adversely impact profitability and overall business performance
IPO FAQs
The promoters of the company are Rajesh Vasantray Doshi, Kunjal C Dedhia and Krishiv Rajesh Doshi.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.